(Cincinnati, OH—August 24, 2018) Airway Therapeutics, LLC (“Airway”), a biotechnology company focused on developing new interventions for acute and chronic lung diseases, announces the appointment of Paul Kingma, MD, PhD to the position of Chief Medical Officer (“CMO”) as of August 1, 2018 in preparation for clinical development of AT-100, a recombinant form of human surfactant protein-D.
Dr. Kingma’s focus includes surfactant protein-D (“SP-D”) and its role in the pathogenesis of lung diseases, particularly in neonates; the development of the preterm lung; and bronchopulmonary dysplasia (“BPD”). Paul has been instrumental in supporting Airway with the development of the AT-100 formulation, analytical assays and animal experiments. He is also a member of Airway’s Scientific Advisory Board. Paul will assume his new role at Airway while maintaining some of his current roles at Cincinnati Children’s Hospital Medical Center.
Paul is Neonatal Director at the Cincinnati Fetal Center, Co-Director of the Cincinnati Bronchopulmonary Dysplasia Center, Attending Neonatologist at Cincinnati Children’s Hospital and Associate Professor of Pediatrics in the UC Department of Pediatrics. He has led numerous clinical and basic science studies, and has researched the biological activity and therapeutic potential of surfactant protein-D since 2001.
“Paul is the perfect match for Airway. He is a highly recognized expert in neonatology, BPD and SP-D, and he is a team player with great leadership skills,” said Marc Salzberg, CEO of Airway Therapeutics.
As CMO, Paul will lead the development of clinical studies with AT-100 and continue to help guide the current pre-clinical activities in preparation for clinical trials.
John Rice, Chairman of the Board of Airway, said, “We are excited to have Paul joining the company and preparing the clinical stage development of AT-100 with the Airway team.”
ABOUT AIRWAY THERAPEUTICS
Airway Therapeutics is a biotechnology company focused on developing new interventions for acute and chronic lung diseases in the most vulnerable of patients. Founded in 2011 as a spin-out of Cincinnati Children’s Hospital Medical Center, Airway Therapeutics has extensive expertise in protein development for applications in the lungs and pediatrics. Airway Therapeutics is currently developing an investigational product, AT-100, a recombinant form of human surfactant protein-D (rhSP-D), for the prevention of a serious lung condition called bronchopulmonary dysplasia (BPD) in preterm neonates.
CONTACT: Sandra Roberts email@example.com